Market Cap 721.88M
Revenue (ttm) 0.00
Net Income (ttm) -126.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,419,700
Avg Vol 1,166,882
Day's Range N/A - N/A
Shares Out 49.72M
Stochastic %K 79%
Beta -0.04
Analysts Strong Sell
Price Target $30.89

Company Profile

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegra...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
55 Cambridge Parkway, Suite 901 East, Cambridge, United States
Dragonfly41
Dragonfly41 Jul. 15 at 9:59 PM
$KALV $20 coming tmrw
1 · Reply
TwongStocks
TwongStocks Jul. 15 at 8:19 PM
$KALV Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema https://www.businesswire.com/news/home/20250715103754/en/KalVista-Pharmaceuticals-Announces-UK-MHRA-Approval-of-EKTERLY-sebetralstat-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema
0 · Reply
Shakattack31
Shakattack31 Jul. 15 at 8:08 PM
0 · Reply
ProfitFireStorm
ProfitFireStorm Jul. 15 at 7:49 PM
$CYCC $KALV $PLRZ $PTHS After hours beasts!!!!!! Which one will breakout?????? 🤔🤔🌋🌋🌋🌋⚡️⚡️⚡️⚡️⚡️⚡️
0 · Reply
Dragonfly41
Dragonfly41 Jul. 15 at 7:35 PM
$KALV I bought some here Looks promising
0 · Reply
Moose94
Moose94 Jul. 15 at 6:47 PM
$TNXP $AQST $KALV $URGN lets goooo
0 · Reply
Zerocool510
Zerocool510 Jul. 15 at 6:10 PM
$KALV posted today updating todays Approval and gave a little update on US launch. Monday boys and gals!
0 · Reply
TwongStocks
TwongStocks Jul. 15 at 3:18 PM
$KALV US and UK approvals for EKTERLY in hand. EU approval should be coming up as well. Japan approval a bit later (early 2026). From the license agreement with Kaken Pharma, KALV will receive $11M with an approval in Japan.
0 · Reply
TwongStocks
TwongStocks Jul. 15 at 3:15 PM
$KALV Link for the UK approval https://www.gov.uk/government/news/mhra-approves-sebetralstat-ekterly-to-treat-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-over
0 · Reply
geegor
geegor Jul. 15 at 1:49 PM
$KALV 07/15/2025 08:51 AM EDT, (MT Newswires) -- The UK Medicines and Healthcare products Regulatory Agency, or MHRA, cleared KalVista Pharmaceuticals' (4XC1.F) Ekterly drug as a treatment for hereditary angioedema attacks. Ekterly, or sebetralstat, is the first and only MHRA-approved oral and on-demand treatment for the condition characterized by sudden swelling, according to a Tuesday release. It is indicated for use in adults and adolescents aged 12 and above. The authorization was supported by the Konfident clinical study, in which Ekterly significantly decreased the time from attack to symptom relief and full attack resolution, versus placebo.
1 · Reply
Latest News on KALV
US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 8 days ago

US FDA approves KalVista Pharma's swelling disorder drug


KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 3 months ago

KalVista: Poised For Rare Disease Transformation


KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 16, 2024, 7:00 AM EST - 7 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer


KalVista Appoints Brian Piekos as Chief Financial Officer

Sep 10, 2024, 6:30 AM EDT - 11 months ago

KalVista Appoints Brian Piekos as Chief Financial Officer


Dragonfly41
Dragonfly41 Jul. 15 at 9:59 PM
$KALV $20 coming tmrw
1 · Reply
TwongStocks
TwongStocks Jul. 15 at 8:19 PM
$KALV Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema https://www.businesswire.com/news/home/20250715103754/en/KalVista-Pharmaceuticals-Announces-UK-MHRA-Approval-of-EKTERLY-sebetralstat-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema
0 · Reply
Shakattack31
Shakattack31 Jul. 15 at 8:08 PM
0 · Reply
ProfitFireStorm
ProfitFireStorm Jul. 15 at 7:49 PM
$CYCC $KALV $PLRZ $PTHS After hours beasts!!!!!! Which one will breakout?????? 🤔🤔🌋🌋🌋🌋⚡️⚡️⚡️⚡️⚡️⚡️
0 · Reply
Dragonfly41
Dragonfly41 Jul. 15 at 7:35 PM
$KALV I bought some here Looks promising
0 · Reply
Moose94
Moose94 Jul. 15 at 6:47 PM
$TNXP $AQST $KALV $URGN lets goooo
0 · Reply
Zerocool510
Zerocool510 Jul. 15 at 6:10 PM
$KALV posted today updating todays Approval and gave a little update on US launch. Monday boys and gals!
0 · Reply
TwongStocks
TwongStocks Jul. 15 at 3:18 PM
$KALV US and UK approvals for EKTERLY in hand. EU approval should be coming up as well. Japan approval a bit later (early 2026). From the license agreement with Kaken Pharma, KALV will receive $11M with an approval in Japan.
0 · Reply
TwongStocks
TwongStocks Jul. 15 at 3:15 PM
$KALV Link for the UK approval https://www.gov.uk/government/news/mhra-approves-sebetralstat-ekterly-to-treat-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-over
0 · Reply
geegor
geegor Jul. 15 at 1:49 PM
$KALV 07/15/2025 08:51 AM EDT, (MT Newswires) -- The UK Medicines and Healthcare products Regulatory Agency, or MHRA, cleared KalVista Pharmaceuticals' (4XC1.F) Ekterly drug as a treatment for hereditary angioedema attacks. Ekterly, or sebetralstat, is the first and only MHRA-approved oral and on-demand treatment for the condition characterized by sudden swelling, according to a Tuesday release. It is indicated for use in adults and adolescents aged 12 and above. The authorization was supported by the Konfident clinical study, in which Ekterly significantly decreased the time from attack to symptom relief and full attack resolution, versus placebo.
1 · Reply
Shakattack31
Shakattack31 Jul. 15 at 6:47 AM
$KALV where is the Best site to be updated on biotech news?
1 · Reply
Zerocool510
Zerocool510 Jul. 15 at 12:21 AM
$KALV anyone have a guess what the stock price will be around by the time this stock offering is done?
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 9:53 PM
$TNXP another important point to keep in mind: they’re running the ATM now so they can announce a much improved cash on hand next month at the earnings call. They want a cash runway to support the launch and the pipeline through 2026 so that @BigPharma doesn’t think the Tonix board is desperate (they shouldn’t be). Approval could come early like it did for $NUVB , or late like it did for $KALV (these are three of my Biotech Fantastic Five). There will be a healthy debate on if / when Tonix should be acquired. Being a Celgene alum… I kind of want to let it ride. Or, rather, soar. 🚀 Still buying shares. I won’t be able to catch up with @Proposition_Joe as the top @Stocktwits TNXP Owner by the PDUFA but I’ll be fine with second or third place 😆 $ALT & $IMRX are also in my top 5. Here we forking go! 🥗 Less than 5 work weeks until PDUFA… 🕰️ or, a month and a day away!
2 · Reply
RunnerSignals
RunnerSignals Jul. 14 at 8:13 PM
These stocks hit the lows but said "not today" and surged back big $MCRB $IOBT $ASPI $KALV $LEU showing resilience with style
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 8:09 PM
$APLS hmm another rare disease PDUFA looming like $KALV . How are you all feeling about pegcetacoplan’s approval odds? 🚀 As good as $TNXP ‘s? 🧐
2 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 7:16 PM
$KALV is a very different company than $NUVB but they’re both in similar situations. Both were just approved and sold off for no good reason (all of biopharma sold off due to CAPT & RARE’s CRL’s last Friday- even $TNXP which has the most upside of all of these 🚀) Both are currently undervalued by 100-200% and could be bought by BP at any minute.
0 · Reply
Trust121
Trust121 Jul. 14 at 6:45 PM
$KALV Watching
0 · Reply
Shakattack31
Shakattack31 Jul. 14 at 3:48 PM
$KALV so ? Where do you think its going ?
2 · Reply
Shakattack31
Shakattack31 Jul. 14 at 9:27 AM
$KALV hope you took some profit 🫣
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 1:29 AM
I’m a huge $ALT bull. They got screwed on their phase 2 B results because a few placebo patients outperformed. Long term they should turn it around. I need to do some research into $UNCY . HypoP seems pretty treatable so reaching its approval (if granted) may be difficult. I see that UNCY had a late June PDUFA which came and went. Did they get screwed by Makary like $KALV $NVAX & $GSK too? 😤
2 · Reply
Shakattack31
Shakattack31 Jul. 13 at 2:51 PM
$KALV I don't understand the story – the agreement allowing share dilution was already known back in April 2025. So why is it making headlines only now? Is there a reliable source confirming that they actually triggered this clause, or is it just speculation?
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 13 at 1:41 PM
$NUVB even more powerful and horned than the bull is the triceratops (RIP). Here, I asked Grok to draw me a green triceratops charging down Wall Street in support of Ibtrozi’s launch. I am a Nuvation bull - and triceratops! 🐂 🧬 🦖 $TNXP $KALV $VKTX $IMRX are also undervalued 🤫
1 · Reply